Lexeo Therapeutics, Inc. $LXEO Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC cut its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 9.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,976,429 shares of the company’s stock after selling 533,206 shares during the quarter. Janus Henderson Group PLC owned approximately 0.06% of Lexeo Therapeutics worth $28,510,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LXEO. Allworth Financial LP raised its holdings in shares of Lexeo Therapeutics by 1,002.9% during the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after acquiring an additional 3,079 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after acquiring an additional 1,459 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lexeo Therapeutics during the fourth quarter worth approximately $37,000. California State Teachers Retirement System increased its position in shares of Lexeo Therapeutics by 123.7% during the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Lexeo Therapeutics by 160.2% in the 4th quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company’s stock valued at $58,000 after purchasing an additional 3,615 shares during the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $4.13 on Monday. Lexeo Therapeutics, Inc. has a one year low of $4.03 and a one year high of $10.99. The stock has a market cap of $324.30 million, a PE ratio of -2.85 and a beta of 1.42. The stock has a 50 day moving average price of $4.69 and a 200 day moving average price of $5.81.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. As a group, analysts predict that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on LXEO. JPMorgan Chase & Co. decreased their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Weiss Ratings lowered shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Chardan Capital upgraded shares of Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $18.75.

Insiders Place Their Bets

In other news, insider Narinder Pal Bhalla sold 22,306 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the transaction, the insider owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. The trade was a 21.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56. Following the completion of the sale, the chief executive officer directly owned 377,817 shares of the company’s stock, valued at $1,692,620.16. This represents a 6.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 62,204 shares of company stock valued at $280,089 over the last ninety days. Corporate insiders own 2.00% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.